A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis

European Respiratory Journal

Volumn 50, Issue 6, 2017, Pages

  Miotto, Paolo ^a   Tessema, Belay ^b   Tagliani, Elisa ^a   Chindelevitch, Leonid ^c   Starks, Angela M ^d   Emerson, Claudia ^e   Hanna, Debra ^f   Kim, Peter S ^g   Liwski, Richard ^f   Zignol, Matteo ^h   Gilpin, Christopher ^h   Niemann, Stefan ^i,j   Denkinger, Claudia M ^k   Fleming, Joy ^l   Warren, Robin M ^m   Crook, Derrick ^n,o   Posey, James ^d   Gagneux, Sebastien ^p,q   Hoffner, Sven ^r,s   Rodrigues, Camilla ^t   Comas, Iñaki ^u,v,w   Engelthaler, David M ^x   Murray, Megan ^y   Alland, David ^z   Rigouts, Leen ^aa   Lange, Christoph ^i,r,ab,ac   Dheda, Keertan ^ad   Hasan, Rumina ^ae   Ranganathan, Uma Devi K ^af   McNerney, Ruth ^ag   Ezewudo, Matthew ^f   Cirillo, Daniela M ^a   Schito, Marco ^f   Köser, Claudio U ^ah   Rodwell, Timothy C ^k,ai   more..

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF GONDAR   (Ethiopia)

^c SIMON FRASER UNIVERSITY   (Canada)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f CRITICAL PATH INSTITUTE   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

ⁱ RESEARCH CENTER BORSTEL   (Germany)

^j German Center for Infection Research   (Germany)

^k FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

^l INSTITUTE OF BIOPHYSICS   (China)

^m UNIVERSITY OF STELLENBOSCH   (South Africa)

ⁿ UNIVERSITY OF OXFORD   (United Kingdom)

^o PUBLIC HEALTH ENGLAND   (United Kingdom)

^p SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^q UNIVERSITY OF BASEL   (Switzerland)

^r KAROLINSKA INSTITUTE   (Sweden)

^s SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^t P D HINDUJA NATIONAL HOSPITAL   (India)

^u CSIC   (Spain)

^v Foundation for the Promotion of Health and Biomedical Research in the Valencian Region   (Spain)

^w CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^x TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^y HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^z RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^aa INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^ab UNIVERSITY OF LÜBECK   (Germany)

^ac UNIVERSITY OF NAMIBIA   (Namibia)

^ad UNIVERSITY OF CAPE TOWN   (South Africa)

^ae AGA KHAN UNIVERSITY   (Pakistan)

^af NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^ag UNIVERSITY OF CAPE TOWN   (South Africa)

^ah UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^ai UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CAPREOMYCIN; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; BACTERIAL DNA; BACTERIAL PROTEIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; DRUG SENSITIVITY; EIS GENE; ETHA GENE; FURA GENE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; GIDB GENE; GYRA GENE; GYRB GENE; HUMAN; INHA GENE; KATG GENE; MSHA GENE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PNCA GENE; PRIORITY JOURNAL; RPOB GENE; RPSL GENE; RRS GENE; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; TLYA GENE; DNA SEQUENCE; DRUG EFFECT; GENETICS; GENOTYPE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MUTATION; STATISTICAL ANALYSIS;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DATA INTERPRETATION, STATISTICAL; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; SEQUENCE ANALYSIS, DNA; SYSTEMATIC REVIEWS AS TOPIC; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85043462793     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01354-2017     Document Type: Article

References (52)

1. World Health Organization. Global Tuberculosis Report 2016. Geneva, World Health Organization, 2016.
2. Ahuja SD, Ashkin D, Avendano M, et al Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9: e1001300.
3. Migliori GB, Sotgiu G, Gandhi NR, et al Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
4. Falzon D, Schünemann HJ, Harausz E, et al World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49: 1602308.
5. Borisov SE, Dheda K, Enwerem M, et al Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J 2017; 49: 1700387.
6. Tadolini M, Garcia-Prats AJ, D'Ambrosio L, et al Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. Eur Respir J 2016; 48: 938-943.
7. Pontali E, Sotgiu G, D'Ambrosio L, et al Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J 2016; 47: 394-402.
8. Pym AS, Diacon AH, Tang SJ, et al Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 2016; 47: 564-574.
9. Schön T, Miotto P, Köser CU, et al Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives. Clin Microbiol Infect 2017; 23: 154-160.
10. Walker TM, Merker M, Kohl TA, et al Whole genome sequencing for M/XDR tuberculosis surveillance and for resistance testing. Clin Microbiol Infect 2017; 23: 161-166.
11. Ellington MJ, Ekelund O, Aarestrup FM, et al The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee. Clin Microbiol Infect 2017; 23: 2-22.
12. Dheda K, Gumbo T, Maartens G, et al The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med 2017; in press [https://doi.org/10.1016/S2213-2600(17)30079-6].
13. Nebenzahl-Guimaraes H, Jacobson KR, Farhat MR, et al Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 2014; 69: 331-342.
14. Walker TM, Kohl TA, Omar SV, et al Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis 2015; 15: 1193-1202.
15. Stucki D, Gagneux S. Single nucleotide polymorphisms in Mycobacterium tuberculosis and the need for a curated database. Tuberculosis 2013; 93: 30-39.
16. Salamon H, Yamaguchi KD, Cirillo DM, et al Integration of published information into a resistance-associated mutation database for Mycobacterium tuberculosis. J Infect Dis 2015; 211: Suppl. 2, S50-S57.
17. Phelan J, O'Sullivan DM, Machado D, et al The variability and reproducibility of whole genome sequencing technology for detecting resistance to anti-tuberculous drugs. Genome Med 2016; 8: 132.
18. Starks AM, Avilés E, Cirillo DM, et al Collaborative effort for a centralized worldwide tuberculosis relational sequencing data platform. Clin Infect Dis 2015; 61: Suppl. 3, S141-S146.
19. Whiting PF, Rutjes AW, Westwood ME, et al QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529-536.
20. Hayden SR, Brown MD Likelihood ratio: a powerful tool for incorporating the results of a diagnostic test into clinical decisionmaking. Ann Emerg Med 1999; 33: 575-580.
21. Goodman SN. Toward evidence-based medical statistics. 2: the Bayes factor. Ann Intern Med 1999; 130: 1005-1013.
22. Brown MD, Reeves MJ Evidence-based emergency medicine/skills for evidence-based emergency care. Interval likelihood ratios: another advantage for the evidence-based diagnostician. Ann Emerg Med 2003; 42: 292-297.
23. Borrell S, Gagneux S. Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis. Clin Microbiol Infect 2011; 17: 815-820.
24. Köser CU, Bryant JM, Parkhill J, et al Consequences of whiB7 (Rv3197A) mutations in Beijing genotype isolates of the Mycobacterium tuberculosis complex. Antimicrob Agents Chemother 2013; 57: 3461.
25. Fonseca JD, Knight GM, McHugh TD The complex evolution of antibiotic resistance in Mycobacterium tuberculosis. Int J Infect Dis 2015; 32: 94-100.
26. Feuerriegel S, Köser CU, Niemann S. Phylogenetic polymorphisms in antibiotic resistance genes of the Mycobacterium tuberculosis complex. J Antimicrob Chemother 2014; 69: 1205-1210.
27. Sander P, Meier A, Böttger EC. Ribosomal drug resistance in mycobacteria. Res Microbiol 1996; 147: 59-67.
28. Reeves AZ, Campbell PJ, Willby MJ, et al Disparities in capreomycin resistance levels associated with the rrs A1401G mutation in clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2015; 59: 444-449.
29. Coll F, McNerney R, Preston MD, et al Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. Genome Med 2015; 7: 51.
30. Farhat MR, Sultana R, Iartchouk O, et al Genetic determinants of drug resistance in Mycobacterium tuberculosis and their diagnostic value. Am J Respir Crit Care Med 2016; 194: 621-630.
31. World Health Organization. High-priority Target Product Profiles for New TB Diagnostics: Report of a Consensus Meeting. Geneva, World Health Organization, 2014.
32. Ajileye A, Alvarez N, Merker M, et al Some synonymous and nonsynonymous gyrA mutations in Mycobacterium tuberculosis lead to systematic false-positive fluoroquinolone resistance results with the Hain GenoType MTBDRsl assays. Antimicrob Agents Chemother 2017; 61: e02169-16.
33. Hain Lifescience. GenoType MTBDRplus ver 2.0. Instructions for Use. 2012.
34. Hain Lifescience. GenoType MTBDRsl ver 2.0. Instructions for Use. 2015.
35. Rigouts L, Gumusboga M, de Rijk WB, et al Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol 2013; 51: 2641-2645.
36. Kambli P, Ajbani K, Sadani M, et al Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay. Tuberculosis 2015; 95: 137-141.
37. Coeck N, de Jong BC, Diels M, et al Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis. J Antimicrob Chemother 2016; 71: 1233-1240.
38. Gonzalo X, Claxton P, Brown T, et al True rifampicin resistance missed by the MGIT: prevalence of this pheno/genotype in the UK and Ireland after 18 month surveillance. Clin Microbiol Infect 2017; 23: 260-263.
39. Rahman A, Sahrin M, Afrin S, et al Comparison of Xpert MTB/RIF assay and GenoType MTBDRplus DNA probes for detection of mutations associated with rifampicin resistance in Mycobacterium tuberculosis. PLoS One 2016; 11: e0152694.
40. Campbell PJ, Morlock GP, Sikes RD, et al Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55: 2032-2041.
41. Grimes DA, Schulz KF Refining clinical diagnosis with likelihood ratios. Lancet 2005; 365: 1500-1505.
42. Altman DG, Bland JM Diagnostic tests 2: predictive values. BMJ 1994; 309: 102.
43. Boyko EJ. Ruling out or ruling in disease with the most sensitive or specific diagnostic test: short cut or wrong turn? Med Decis Making 1994; 14: 175-179.
44. Rubin A, Bellamy J. Practitioner's Guide to Using Research for Evidence-Based Practice. 2nd Edn. Chichester, Wiley, 2012.
45. Canetti G, Fox W, Khomenko A, et al Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
46. Zaunbrecher MA, Sikes RD Jr, Metchock B, et al Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2009; 106: 20004-20009.
47. Ando H, Miyoshi-Akiyama T, Watanabe S, et al A silent mutation in mabA confers isoniazid resistance on Mycobacterium tuberculosis. Mol Microbiol 2014; 91: 538-547.
48. Safi H, Lingaraju S, Amin A, et al Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-β-D-arabinose biosynthetic and utilization pathway genes. Nat Genet 2013; 45: 1190-1197.
49. Van Deun A, Aung KJ, Bola V, et al Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 2013; 51: 2633-2640.
50. Willby M, Sikes RD, Malik S, et al Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2015; 59: 5427-5434.
51. Clinical and Laboratory Standards Institute. M24-A2 Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard - Second Edition. Wayne, Clinical and Laboratory Standards Institute, 2011.
52. Rigouts L, Coeck N, Gumusboga M, et al Specific gyrA gene mutations predict poor treatment outcome in MDR-TB. J Antimicrob Chemother 2016; 71: 314-323.